Oscotec R&D Day

June 24, 2025

Taeyoung Yoon, Ph.D.

CEO



Disclaimer

This presentation has been prepared by Oscotec Inc.(the "Company") solely for its own use at its presentation to company investors.

Information contained herein is strictly confidential, and is given only for your information and for your use and may not be copied, reproduced, distributed, redistributed or passed on, directly or indirectly, to any other person in any manner, or published, in whole or in part, for any purpose. Certain statements contained herein constitute forward-looking statements that are based on management's expectations, estimates, projections and assumptions. Words such as "anticipates," "plans," "estimates," "expects" and variations of these words and similar expressions are intended to identify forward-looking statements. Such statements address future financial results and business standings.

Forward-looking statements are not guarantees of future performance and involve certain uncertainties and risks, which are affected by further changes in business environment. Therefore, actual future results and trends may differ materially from the forecasts reflected in the forward-looking statements herein due to a variety of factors including but not limited to the changes in market conditions and strategy revisions.

The Company is not liable for any investment decisions by its readers or subscribers and does not undertake any legal obligation to present any supporting evidence against investment results of investors under any circumstances.



Highlights

- Cevidoplenib
 - P2 (IIT, 1st line ITP) IND filed (MFDS)
 - BD activity update
- Denfivontinib
 - Deprioritized in solid tumor; AML to be revisited
- > ADEL-Y01
 - P1 progressing smoothly; Part B (MAD) initiated
- ➤ OCT-598
 - IND cleared by FDA; FIH dosing to start in Q4
 - AACR presentation
- Cancer Therapy Resistance
 - The first target disclosed in AACR (NUAK1/2)

[BD = Business Development; IIT =
Investigator-Initiated Trial; ITP = Immune
Thrombocytopenia; AML = Acute myeloid
leukemia; MAD = Multiple Ascending
Dose; FIH = First-in-human]



Cevidoplenib

- Highly potent and selective SYK inhibitor
- Quick entry to market; immune thrombocytopenia (ITP)
 - Orphan drug designated
 - Proven efficacy and safety in P2 (2nd line); P3-ready
 - Potential expansion to the 1st line (IIT to start in 2025)
- 'Pipeline in a product' indication expansion
 - Rheumatoid arthritis (precision immunology for 'early RA')
 - wAIHA, cGVHD, AbMR, AAV, etc
- > Partnering activities
 - Commercialization in ITP (global/regional)
 - PoC in RA subpopulation (precision immunology)

IIT = Investigator-initiated trial; wAIHA = warm Autoimmune Hemolytic Anemia; cGVHD = chronic Graft-versus-Host Disease; AbMR = Antibody-mediated (organ transplantation) Rejection; AAV = ANCA-Associated Vasculitis; PoC = Proof of Concept



ADEL-Y01

- ➤ Anti-tau antibody targeting a pathological form of tau protein (AcK280) to treat tauopathies including Alzheimer Disease
- First-in-human study underway (US)
 - First in Human, Phase Ia/b study for safety, tolerability, pharmacokinetics, and clinical activity evaluation of ADEL-Y01 in healthy participants and in participants with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease
 - P1a (SAD) dosing completed (2.5 ~ 100 mg/kg)
 - No safety concern reported to date
 - PK exposure exceeding prediction; q4w possible
 - P1b (MAD) study initiated; enrolling MCI/AD patients
- Partnership discussion ongoing

SAD = Single Ascending Dose; MAD = Multiple Ascending Dose; PK = Pharmacokinetics; q4w = dosing every 4 weeks



OCT-598

- > EP2/4 dual antagonist for cancer therapy resistance
 - Will OCT-598 combination delay the development of resistance and prolong the responses to standard-of-care anti-tumor therapies?
- > IND cleared by US FDA
 - A Phase 1 Dose-Escalation Study to Evaluate the Safety, Tolerability,
 Pharmacokinetics, and Efficacy of OCT-598 as a Single Agent and in
 Combination With Standard-of-Care Treatment in Patients With Advanced
 Solid Tumors
 - IND to be filed in MFDS, FIH dosing to start in Q4
 - To begin with docetaxel combination in multiple tumor types (lung, breast, prostate, gastric, and head and neck cancer); potentially expand to other combinations

FIH = First-in-human





Inhibition of PGE2 Signaling by An EP2/4 Dual Antagonist OCT-598 Prevents Acquisition of Therapyresistance And Tumor Relapse

Youngrae Lee¹, Hain Choi¹, Jong-Won Lim¹, Sung Eun Lee², Yeeun Kim², Changhoon Choi², Taeyoung Yoon¹


¹Oscotec Inc., Seongnam, Korea, Republic of, ²Samsung Medical Center, Seoul, Korea, Republic of



Introduction




- Prostaglandin E2 (PGE2): Regenerative Signal Driving Resistance
 - Therapy-induced cancer cell death activates the "Phoenix Rising" pathway, producing PGE2
 - PGE2 promotes regenerative and immunosuppressive niche formation, via EP2 and EP4, in TME




❖ OCT-598, EP2/4 dual antagonist

 OCT-598 induced complete regression and durable responses in a mouse syngeneic TC-1 tumor model when combined with standard of care (SoC) chemo-immunotherapy (Abstract #3234, AACR 2023).












Tumor Repopulation after Docetaxel Treatment




H460 lung cancer cell line with red fluorescently labeled nuclei











OCT-598, Inhibition of Tumor Repopulation In Vitro



H460 lung cancer cell line with red fluorescently labeled nuclei




DNA Content (Flow cytometer)




Inhibition of Post-Therapy Tumor Relapse — **In Vivo PoC Study**




NCI-H460 Lung Tumor Xenograft Mouse Model






CT26 Colon Tumor Syngeneic Mouse Model



OCT-598, Clinical Development Plan



- We aim to develop OCT-598 as an 'antiresistance' agent to prevent tumor cells from acquiring resistance to SoC therapies.
- Strategic Plan
 - Rapid initiation of combination dosefinding studies with SoC therapies.
 - Initial combination will be with docetaxel.
 - Additional combination regimens will be explored in future stages.



Oct | Oscotec Inc.



Pharmacological inhibition of NUAK1/2 synergizes with chemotherapy in pancreatic cancer models by abrogating drug resistance and suppressing fibrosis

Minji Seo, Jihye Yoon, Song-Eun Park, Jong-Won Lim, Sungho Park, Yuntae Kim, <u>Taeyoung Yoon</u> OSCOTEC Inc., Seongnam, Korea.





Background and Hypothesis

Ploidy cycle mediates cancer therapy resistance

YAP activation unlocks the entry to ploidy cycle


NUAK1/2 feed forward YAP activation









Ploidy-mediated Repopulation of PDAC Cells after Gemcitabine



 Upon gemcitabine treatment, surviving PDAC cells become hyperploid before giving birth to para-diploid daughter cells



 The daughter cells remain sensitive to gemcitabine, but enter the next ploidy cycle much more readily





NUAK1/2 Inhibitor P4899 Abrogates Repopulation In Vitro

P4899 inhibits TGFβ-mediated fibroblast activation In vitro activities of P4899 Vehicle P4899 LATS1/β-actin P4899 IC₅₀ **TGFB** Nucleus 0.9 nM NUAK1 NUAK2 51.4 nM EC₅₀: 322.4 nM MiaPaCa2 MiaPaCa2 **Control** Gem 8×106 growth Gem+P4899 6×10⁶ repopulation after gemcitabine 4×10⁶ Dose-dependent inhibition of Inhibition of tumorsphere Day Gem BxPC3 BxPC3 Area (µm²) Gem/P4899 CFPAC1 CFPAC1 € 30 Area (µm²) 3×106 듈 20-

Day

Day 0

10

5




Gemcitabine + P4899


NUAK1/2 Inhibitor P4899 Alleviates Fibrosis In Vivo

Vehicle

Mouse KPC orthotopic tumor model




Tumor growth inhibition



> P4899 significantly reduced gemcitabine-induced fibrosis

Gemcitabine



Q&A

